피나스테리드(Finasteride) 시장 기회, 성장요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Finasteride Market was valued at USD 130.8 million in 2025 and is estimated to grow at a CAGR of 2.4% to reach USD 165.8 million by 2035.

Despite facing competition from other drugs in its class and pressure from lower-priced generics, finasteride continues to experience steady growth. This expansion is driven by newly approved indications, broader acceptance in the medical community, and increasing prescription rates. While mature markets in the US, Canada, and Western Europe have reached near-saturation, showing limited growth, demand in Eastern Asia and India continues to rise. Factors such as higher income levels, increased spending on personal appearance, growing awareness of benign prostatic hyperplasia (BPH) and androgenetic alopecia, and better access to specialist care are fueling this trend. This strong and sustained demand is expected to continue over the coming years, supporting long-term market stability.

The androgenetic alopecia segment held 42.6% share in 2025 and is expected to grow at a CAGR of 2% through 2035. Finasteride is primarily prescribed for BPH and androgenetic alopecia. BPH is prevalent among older men, creating a stable patient base primarily managed through urology and primary care. Male pattern hair loss, affecting younger patients, has fueled adoption through dermatology, tele-dermatology, and direct-to-consumer programs across North America, Europe, and Asia.

The retail and community channel segment held a 61% share in 2025 and is anticipated to grow at a CAGR of 3.4% through 2035. Prescription finasteride continues to be dispensed mainly via traditional retail and community channels, including independent pharmacies and chain drug stores. Hospital pharmacies support inpatient care and specialist-initiated therapy, particularly in urology, while dermatology and trichology clinics in urban areas often serve as primary prescribers and influencers.

North America Finasteride Market accounted for USD 34.1 million in 2025, and is expected to reach USD 43.5 million by 2035. Growth in the region is supported by stable BPH prescriptions, widespread generic availability, high diagnostic rates, robust urology and dermatology networks, and the expanding use of tele-dermatology for hair loss. Price growth, however, remains constrained due to reimbursement policies and generic competition.

Key players operating in the Global Finasteride Market include Merck & Co., Inc. (MSD), Teva Pharmaceutical Industries Ltd., Sandoz (Novartis division), Mylan (Viatris Inc.), Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals plc, and Apotex Inc. Companies in the Global Finasteride Market are adopting multiple strategies to strengthen their presence and expand market share. They are launching new generic formulations to increase accessibility and compete on price while maintaining quality standards. Strategic partnerships and licensing agreements with regional manufacturers help widen distribution networks and penetrate emerging markets. Investments in marketing, physician education, and telemedicine platforms enhance awareness and adoption, particularly for androgenetic alopecia treatment.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Therapeutic application
  • 2.2.3 Dosage strength
  • 2.2.4 Distribution channel
  • 2.2.5 Application
• 2.3 TAM Analysis, 2026-2035
• 2.4 CXO perspectives: Strategic imperatives
  • 2.4.1 Executive decision points
  • 2.4.2 Critical success factors
• 2.5 Future Outlook and Strategic Recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Profit margin
  • 3.1.3 Value addition at each stage
  • 3.1.4 Factor affecting the value chain
  • 3.1.5 Disruptions
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising BPH burden in aging male populations
    • 3.2.1.2 Increasing aesthetic focus on hair-loss treatment
    • 3.2.1.3 Widening access to low-cost generics
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Safety concerns and black-box style warnings
    • 3.2.2.2 Strong generic competition and reimbursement pressure
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion of digital prescribing and e-pharmacy channels
    • 3.2.3.2 Combination regimens with minoxidil and new agents
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East & Africa
• 3.5 Porter's analysis
• 3.6 PESTEL analysis
• 3.7 Price trends
  • 3.7.1 By region
  • 3.7.2 By Therapeutic application
• 3.8 Future market trends
• 3.9 Technology and Innovation landscape
  • 3.9.1 Current technological trends
  • 3.9.2 Emerging technologies
• 3.10 Patent Landscape
• 3.11 Trade statistics (HS code) (Note: the trade statistics will be provided for key countries only)
  • 3.11.1 Major importing countries
  • 3.11.2 Major exporting countries
• 3.12 Sustainability and environmental aspects
  • 3.12.1 Sustainable practices
  • 3.12.2 Waste reduction strategies
  • 3.12.3 Energy efficiency in production
  • 3.12.4 Eco-friendly initiatives
• 3.13 Carbon footprint consideration

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 By region
    • 4.2.1.1 North America
    • 4.2.1.2 Europe
    • 4.2.1.3 Asia Pacific
    • 4.2.1.4 LATAM
    • 4.2.1.5 MEA
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New Product Launches
  • 4.6.4 Expansion Plans

Chapter 5 Market Estimates and Forecast, By Therapeutic Application, 2022-2035 (USD Million) (Kilo Tons)

• 5.1 Key trends
• 5.2 Androgenetic alopecia (male pattern hair loss)
• 5.3 Benign prostatic hyperplasia (BPH)
• 5.4 Female pattern hair loss (selected cases)
• 5.5 Hirsutism and other androgen-mediated conditions
• 5.6 Others

Chapter 6 Market Estimates and Forecast, By Dosage Strength, 2022-2035 (USD Million) (Kilo Tons)

• 6.1 Key trends
• 6.2 Oral 1 mg
• 6.3 Oral 5 mg
• 6.4 Topical ≤ 0.1%
• 6.5 Topical > 0.1% to 0.25%
• 6.6 Topical > 0.25% to 0.5% and above

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2022-2035 (USD Million) (Kilo Tons)

• 7.1 Key trends
• 7.2 Retail and community channels
  • 7.2.1 Community pharmacies
  • 7.2.2 Chain drugstores
  • 7.2.3 Online pharmacies (legally licensed)
• 7.3 Institutional channels
  • 7.3.1 Hospital pharmacies
  • 7.3.2 Specialty clinics (urology, dermatology, trichology)
  • 7.3.3 Direct-to-consumer (DTC) models
• 7.4 Others

Chapter 8 Market Estimates and Forecast, By Application, 2022-2035 (USD Million) (Kilo Tons)

• 8.1 Key trends
• 8.2 Prostate Treatment
  • 8.2.1 Prostate Enlargement
  • 8.2.2 Prostate Cancer
  • 8.2.3 Hormone therapy (Transgender Women)
• 8.3 Hair Treatment
  • 8.3.1 Scalp Hair Loss
  • 8.3.2 Excessive Hair Growth

Chapter 9 Market Estimates and Forecast, By Region, 2022-2035 (USD Million) (Kilo Tons)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Merck & Co., Inc. (MSD)
• 10.2 Teva Pharmaceutical Industries Ltd.
• 10.3 Sandoz (Novartis division)
• 10.4 Mylan (Viatris Inc.)
• 10.5 Sun Pharmaceutical Industries Ltd.
• 10.6 Dr. Reddy’s Laboratories Ltd.
• 10.7 Cipla Ltd.
• 10.8 Aurobindo Pharma Ltd.
• 10.9 Lupin Ltd.
• 10.10 Torrent Pharmaceuticals Ltd.
• 10.11 Hikma Pharmaceuticals plc
• 10.12 Apotex Inc.